Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S. Matsubara N, et al. Among authors: otsuka m. Clin Genitourin Cancer. 2018 Apr;16(2):142-148. doi: 10.1016/j.clgc.2017.09.008. Epub 2017 Sep 23. Clin Genitourin Cancer. 2018. PMID: 29042308
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S. Matsubara N, et al. Among authors: otsuka m. Clin Genitourin Cancer. 2017 Dec;15(6):e1073-e1080. doi: 10.1016/j.clgc.2017.07.016. Epub 2017 Jul 26. Clin Genitourin Cancer. 2017. PMID: 28826931
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
Taguchi S, Buti S, Fukuhara H, Otsuka M, Bersanelli M, Morikawa T, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Taguchi S, et al. Among authors: otsuka m. PLoS One. 2017 Feb 27;12(2):e0172341. doi: 10.1371/journal.pone.0172341. eCollection 2017. PLoS One. 2017. PMID: 28241027 Free PMC article.
Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Matsumoto A, et al. Among authors: otsuka m. World J Urol. 2018 Feb;36(2):249-256. doi: 10.1007/s00345-017-2141-2. Epub 2017 Nov 28. World J Urol. 2018. PMID: 29185045
Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nakagawa T, et al. Among authors: otsuka m. World J Urol. 2017 Oct;35(10):1569-1575. doi: 10.1007/s00345-017-2032-6. Epub 2017 Apr 10. World J Urol. 2017. PMID: 28397000
Clinical significance of random bladder biopsy in primary T1 bladder cancer.
Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Otsuka M, et al. Mol Clin Oncol. 2018 May;8(5):665-670. doi: 10.3892/mco.2018.1587. Epub 2018 Mar 8. Mol Clin Oncol. 2018. PMID: 29725532 Free PMC article.
1,773 results